Published in Cancer Weekly, April 3rd, 1995
J.W. Park et al. remark that HER2 protooncogene and p185HER2, the growth factor receptor-tyrosine kinase it encodes, play a central role in the pathogenesis of many human cancers. Twenty to thirty percent of breast cancers have overexpression of p185HER2, which predicts a poor prognosis for these patients. The p185HER2 receptor is therefore an attractive target for antibody-based therapy ("Development of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.